Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme

Anna J. Lomax, Prue A. Hill, David M. Ashley

Research output: Contribution to journalArticleResearchpeer-review

7 Citations (Scopus)

Abstract

Glioblastoma multiforme is an aggressive malignant brain tumor. The monoclonal antibody, bevacizumab, is active in recurrent disease via inhibition of angiogenesis. Proteinuria and renal thrombotic microangiopathy are known complications. We report a case of a patient developing acute renal failure with biopsy-proven interstitial nephritis while receiving bevacizumab for recurrent disease. The patient was otherwise well with a history of controlled hypertension. Renal function improved with discontinuation of bevacizumab and the administration of corticosteroid therapy.

Original languageEnglish
Pages (from-to)365-368
Number of pages4
JournalJournal of Oncology Pharmacy Practice
Volume19
Issue number4
DOIs
Publication statusPublished - Dec 2013
Externally publishedYes

Keywords

  • bevacizumab
  • Glioblastoma multiforme
  • interstitial nephritis
  • renal failure
  • vascular endothelial growth factor inhibitor

Cite this